Background. Long-term maternal outcomes after postpartum antiretroviral therapy (ART) discontinuation are unknown. Methods. Retrospective review of pregnancies in HIV-infected women on treatment between 1997 and 2005. Women were grouped by postpartum ART use and followed until new opportunistic infection (OI), death or last clinic visit. Results. Of 172 pregnancies, postpartum ART discontinuation occurred in 123 (71.5%) women and was associated with greater parity, no partner during pregnancy, and no indication for OI prophylaxis or preconception ART in multivariate analysis (P < .05). Median follow-up was 32.5 months after delivery. There were 12 OIs and 2 deaths; 10 OIs and both deaths occurred in women who had discontinued ART. Conclusion. Postpartum ART discontinuation is common, especially among those with less advanced HIV disease, but may leave women at increased risk of long term adverse outcomes. This study highlights the need for larger longitudinal studies to determine appropriate recommendations for postpartum ART administration.
Coovadia H.Antiretroviral agents-how best to protect infants from HIV and save their mothers from AIDS. N Engl J Med. 2004;351:289-292.
2.
Cooper ER, Charurat M., Mofenson L., et al; Women and Infants' Transmission Study Group. Combination antiretroviral strategies for the treatment of pregnant HIV-1 infected women and prevention of perinatal HIV-1 transmission. J Acquir Immune Defic Syndr Hum Retrovirol. 2002;29:484-494.
3.
Martin F., Navaratne L., Khan W., et al. Pregnant women with HIV infection can expect healthy survival: three year follow-up. J Acquir Immune Defic Syndr. 2006;43: 186-192.
4.
McIntyre J.Strategies to prevent mother-to-child transmission of HIV. Curr Opin Infect Dis. 2006;19:33-38.
5.
Public Health Service Task Force.Recommendations for use of antiretroviral drugs in pregnant HIV-1 infected women for maternal health and interventions to reduce perinatal HIV-1 transmission in the United States. Accessed on October 2007 from: http://AIDSinfo.nih.org.
6.
Eckman A., Huntley B., Bhuyan A.How to Integrate Gender Into HIV/AIDS Programs: Using Lessons Learnt from USAID and Partner Organizations, Interagency Gender Working Group Task Force Report. Washington, DC: USAID; 2004.
7.
Turner BJ, Newschaffer CJ, Zhang D., Cosler L., Hauck WWAntiretroviral use and pharmacy-based measurement of adherence in postpartum HIV-infected women. Med Care. 2000;38:911-925.
8.
Ikovics JR, Wilson TE, Royce RA, et al; Perinatal Guidelines Evaluation Group.Prenatal and postpartum zidovudine adherence among pregnant women with HIV: results of a MEMS sub-study from the perinatal guidelines evaluation project . J Acquir Immune Defic Syndr. 2002;30:311-315.
9.
Lu MC, Prentice J.The postpartum visit: risk factors for nonuse and association with breastfeeding . Am J Obstet Gynecol. 2002;187:1329-1336.
10.
Jourdain G., Ngo-Giang-Huong N., Le Coeur S., et al; Perinatal HIV Prevention Trial Group.Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy. N Engl J Med.2004 ;351:229-240.
11.
Lyons F., Coughan S., Bryne T., et al. Emergence of genotypic resistance in HIV-1 infected pregnant women taking HAART to reduce mother-to-child transmission of HIV-1. AIDS. 2005;19:63-67.
12.
Duran AS, Losso MH, Salomon H., et al; NISDI Perinatal Study Group.Drug resistance among HIV-infected pregnant women receiving antiretrovirals for prophylaxis. AIDS. 2007;21:199-205.
13.
Benson C., Vaida F., Havlir DV, et al; ACTG A5086 Study Team. A randomized trial of treatment interruption before optimized antiretroviral therapy for persons with drug-resistant HIV: 48-week virologic results of ACTG A5086. J Infect Dis. 2006;194:1309-1318.
14.
El-Sadr W. , Neaton J.Episodic CD4-Guided Use of ART Is Inferior to Continuous Therapy: Results of the SMART Study. 13th CROI. Denver, Colorado; February 2006. Abstract No. 106LB.
15.
Overton ET, Sungkanuparph S., Nurutdinova D., Powderly WGAntiretroviral resistance among HIV-positive pregnant women who have antiretroviral experience from previous pregnancy. AIDS. 2005;19:1439.
16.
Watts DH, Mofenson LM, Lu M., Thompson B.; Women and Infants Transmission Study.Treatment Interruption After Pregnancy and Disease Progression: a Report From the Women and Infants Transmission Study. 14th CROI. Los Angeles, California; Febraury 2007. Abstract No. S109.
17.
Lockman S., Shapiro RL, Smeaton LM, et al; Response to antiretroviral therapy after a single, peripartum dose of nevirapine. N Engl J Med.2007;356:135-147.
18.
Tungsiripat M., Dreschler H., Aberg J.Discontinuation of antiretroviral therapy postpartum. J Aquir Immune Defic Syndr. 2007 ;44:116-117.
19.
Watts DH, Lambert J., Stiehm R., et al; PACTG 185 Study Team.Progression of HIV disease among women following delivery. J Acquir Immune Defic Syndr.2003;33:585-593.
20.
Laine C., Newschaffer CJ, Zhang D., Cosler L., Hauck W., Turner B.Adherence to antiretroviral therapy by pregnant women infected with human immunodeficiency virus: a pharmacy claims-based analysis. Obstet Gynecol. 2000;95:167-173.
21.
Siegel K., Gorey E.HIV-infected women: barriers to AZT use. Soc Sci Med. 1997;45:15-22.
22.
Tedaldi E., Willard S., Gilmore J., Holdsworth C., Dix-Lassiter S., Axelrod P.Continuation of postpartum antiretroviral therapy in a cohort of women infected with human immunodeficiency virus. J Assoc Nurses AIDS Care . 2002;13:60-65.
23.
Warner L., Wei W., McSpiritt E., Sambamoorthi U., Crystal S.Ante-and postpartum substance abuse treatment and antiretroviral therapy among HIV-infected women on Medicaid. J Am Med Womens Assoc. 2003;58:143-153.
24.
Hader SL, Smith DK, Moore JS, Holmberg SDHIV infection in women in the United States. JAMA. 2001;285:1186-1192.
25.
Juethner SN , Willamson C., Ristig MD, Tebas P., Seyfried W., Aberg J.Non-nucleoside reverse transcriptase resistance among antiretroviral-naïve HIV-positive women. J Acquir Immune Defic Syndr. 2003;32:153-156.
26.
Ristig M., Arens MO, Kennedy M., Powderly W., Tebas P.Increasing prevalence of resistance mutations in antiretroviral naïve individuals with established HIVinfection from 1996-2001 in St. Louis. HIV Clin Trials. 2002;3:155-160.
